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ABSTRACT
Objective: The aim of this study was to report the effect on tolerability of 
combined treatment with intravitreal triamcinolone acetonide (IVT) and photody-
namic therapy (PDT) with verteporfin in patients with stage II retinal angiomatous 
proliferation (RAP) who had been treated previously with PDT and presented with 
recurrent RAP (R-RAP).
Methods: This was a retrospective case series of patients with R-RAP after 
PDT (1–5 treatments) treated once with IVT followed 1 month later by PDT. A vi-
sual acuity test, fluorescein and indocyanine green angiography, and optical coherence 
tomography were performed at baseline and at 1, 3, and 6 months.
Results: Five patients (4 men, 1 woman; mean [SD] age, 76.8 [3.9] years) with 
6 eyes diagnosed with stage II R-RAP who had previously been treated with PDT and 
who received an IVT injection and PDT within 1 month were included in the study. 
Best corrected visual acuity (BCVA) remained stable after IVT in 5 eyes (83%) and 
deteriorated in 1 eye (17%). After PDT, BCVA remained stable in 2 eyes (33%) and 
deteriorated in 4 eyes (67%). IVT treatment combined with PDT also reduced fluo-
rescein leakage. Median lesion size increased 24% before PDT and 61% at 6 months 
after PDT. One eye had intraocular hypertension at 3 months, and 1 eye developed a 
pigment epithelial tear after PDT.
Conclusion: The results were limited by the number of eyes and relatively 
short follow-up, but in this study, PDT after IVT did not appear to be as effective or 
well tolerated in 5 patients who had already been treated with PDT and presented with 
R-RAP. (Curr Ther Res Clin Exp. 2009;70:240–251) © 2009 Excerpta Medica Inc.
Key words: intravitreal triamcinolone acetonide, photodynamic therapy, reti-
nal angiomatous proliferation.
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INTRODUCTION
Age-related macular degeneration (AMD) is a degenerative pathology of the posterior 
pole of the retina that is usually associated with visual impairment. It is the most 
common irreversible cause of severe vision loss among older people in Western coun-
tries.1–3 Occult choroidal neovascularization (CNV) occurs in most patients with 
newly diagnosed exudative AMD.4,5 In retinal angiomatous proliferation (RAP), neo-
vascularization begins in the deep retina, extends through the subretinal space, and 
eventually communicates with the choroid, producing a CNV.6 A controversial hy-
pothesis suggests the initial event is the development of an occult chorioretinal anas-
tomosis at the site of a type I CNV (subretinal pigment epithelium [sub-RPE] growth 
pattern) rather than an intraretinal neovascular process.7,8 The prevalence of RAP in 
occult CNV ranges from 20%6 to 28%.9 Both theories describe the severe irreversible 
anatomical and functional course of such aggressive neovascularization.
Ocular photodynamic therapy (PDT) with verteporfin has been reported to re- 
duce vision loss in patients with the classic or predominantly classic type of CNV 
lesions10–12 and with occult CNV lesions but no classic lesions.13 PDT was sug-
gested to improve the anatomic and functional outcomes of RAP.14 Triamcinolone 
and other steroids have been reported to be effective inhibitors of neovas- 
cularization in live and in vitro animal models.15–18 In humans, intravitreal 
triamcinolone acetonide (IVT) combined with verteporfin PDT was well tolerated 
in classic, predominantly classic,19,20 and occult21 CNV lesions. In RAP, remodel-
ing of the vascular lesions was found with the combined use of IVT and PDT,22 
which resulted in functional and anatomic improvement.23 One prospective pilot 
study achieved promising results, but persistent neovascular activity was found in 
7 treated eyes (26%).24
Methods of treating RAP have not been widely established. Surgical ablation of the 
feeding and draining vessels of RAP was reported to have transitory and limited bene- 
ficial effects.25–28 PDT has been proposed to promote stabilization of visual acuity29; 
but the apparent lack of efficacy of this technique suggests that PDT alone does not 
prevent the natural course of the disease.30 Because of the beneficial effects of IVT in 
the management of exudative AMD,31,32 a combination of IVT and PDT was used to 
treat RAP.33 Combination therapy offers the possibility of reducing the number of 
repeated treatments and improving visual acuity.24,34
The aim of this study was to present a case series of combined treatment with IVT 
injection followed 1 month later by PDT in eyes affected by recurrent RAP (R-RAP) 
that had previously been treated with PDT.
PATIENTS AND METHODS
Best corrected visual acuity (BCVA) was measured by Snellen charts at baseline and at 
1, 3, and 6 months. Six consecutive eyes diagnosed with stage II R-RAP after PDT 
in 5 patients who attended the Vitreo-Retinal Center (Policlinico of Bari, Bari, Italy) 
were selected for this single-center, retrospective case series. Institutional review 
board approval or informed consent was not obtained because of the retrospective 
nature of the study. Privacy and confidentiality were maintained per the requirements 
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of Italian law; only doctors from the ophthalmology department at the study site had 
access to the records. Recurrence was determined by residual neovascular activity after 
PDT was detected by fluorescein angiography (ie, leakage due to CNV beyond the 
area of the lesion noted at baseline, regardless of the amount of leakage noted within 
the area of the lesion identified at baseline, and the presence of fibrovascular pigment 
epithelial detachment) and optical coherence tomography (OCT) to identify persistent 
pigment epithelial detachment. Patients were scheduled for a single 25-mg dose of 
IVT followed by PDT 1 month later.
Visual acuity determined using the Early Treatment Diabetic Retinopathy Study 
refraction chart (Precision Vision, La Salle, Illinois) and ophthalmic examination, in-
cluding slit-lamp biomicroscopy, indirect ophthalmoscopy, fluorescein (when avail-
able) and indocyanine green angiography (HRA, Heidelberg Engineering, Heidel-
berg, Germany), and OCT (OCT Stratus, Carl Zeiss Meditec, Inc., Dublin, California) 
were recorded at baseline and at 1, 3, and 6 months. A reduction in leakage was docu-
mented angiographically for occult components using the criteria developed by the 
Macular Photocoagulation Study Group5 and the Treatment of Age-Related Macular 
Degeneration with Photodynamic Therapy Study Group.11,12 All evaluations were 
done by the same investigator (N.C.), who is an experienced retinologist. The greatest 
linear diameter was measured if the lesion was judged to be active. The greatest linear 
dimension (GLD) of the lesion was read on the screen using digital camera software; 
increases in GLD over time indicate worsening disease. The GLD was determined in 
all cases by the same investigator using Imagenet (Topcon TRC-50XT, Topcon Cor-
poration, Tokyo, Japan) digital fluorescein angiography. The GLD measurement in-
cluded all lesion components: the CNV lesions and features that could obscure the 
lesion boundaries (thick blood, hypofluorescence not corresponding to blood, serous 
detachment of the RPE, and hyperfluorescent staining from fibrous tissue).35 Reduc-
tion in retinal thickness and in pigment epithelial detachment was documented by 
OCT, based on the morphology of a 6-mm cross-hair scan centered on the RAP.27 
None of the treated patients had a history or diagnosis of glaucoma. 
Intravitreal Triamcinolone Acetonide Injection
Patients received an intravitreal injection of 25 mg of crystalline triamcinolone 
acetonide in 0.1 mL of balanced salt solution. All injections were performed in the 
operating room by the same surgeon (F.B.). Before the intravitreal injection, topical 
5% povidone/iodine (Alcon Laboratories, Fort Worth, Texas) was applied, and then 
the patients were completely draped. An eye speculum was inserted, and paracentesis 
was done to decrease the volume of the eye. Crystalline triamcinolone acetonide 25 mg 
was injected using a sharp 27-gauge needle through the temporal inferior pars plana 
3 to 3.5 mm from the limbus. A combination antibiotic ointment (polymyxin B sul-
fate and neomycin sulfate) was then applied. The triamcinolone acetonide had been 
prepared by extracting 0.62 mL from an ampule (Kenacort, Bristol-Myers Squibb, 
New York, New York) containing 40 mg of triamcinolone acetonide in 1 mL of bal-
anced salt solution (BSS). The extracted volume was placed in a tuberculin syringe 
(1 mL) filled with BSS. A Millipore filter (pore size, 5 μm [Sterifix Pury, Braun Mel-
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sungen AG, Melsungen, Germany]) was placed on top of the syringe, and most of the 
contents of the syringe were pressed through the filter with the triamcinolone crystals 
remaining in the syringe. The syringe was then refilled with BSS, and the same pro-
cedure was repeated 3 times. At the end, 0.1 mL of solution was left in the syringe 
and injected transconjunctivally into the vitreous cavity. (To our knowledge, there 
have been no studies of this method that validate the actual concentration being in-
jected or its reproducibility.) To avoid an increase in intraocular pressure, all patients 
were given a topical β-blocker (timolol 0.5%) BID for the entire follow-up period.
Photodynamic Therapy
One month after triamcinolone acetonide injection, all eyes underwent PDT. The 
GLD of the lesion was measured on the fluorescein angiogram. Any area of hypofluo-
rescence due to overlying blood or a serous detachment of the RPE contiguous with 
CNV was considered to be part of the GLD of the lesion. Verteporfin (6 mg/m2) was 
infused intravenously for 10 minutes. Fifteen minutes after starting the infusion, a 
laser beam set at 689 nm was delivered at 50 J/cm2 at an intensity of 600 mW/cm2 
for 83 seconds without a safety margin. Each patient was instructed to wear protective 
sunglasses and not expose their eyes to sunlight for the next 2 days.35
Statistical Analysis
All of the data were analyzed using GraphPad Instat (GraphPad Software Inc., San 
Diego, California). Repeated measures analysis of variance tests were used. P < 0.05 
was considered statistically significant. 
RESULTS
Six eyes diagnosed with stage II R-RAP of 5 patients (4 men, 1 woman; mean [SD] age, 
76.8 [3.9] years) who had previously been treated with PDT (mean [SD] number of previ-
ous PDT treatments, 1.8 [1.6]; range, 1–5 treatments) and who received an IVT injection 
(period between primary diagnosis and IVT, 132.3 [143.7] days; range, 11– 408 days) and 
PDT within 1 month (18.3 [6.6] days; range, 11–27 days) were included in the study. The 
BCVA remained stable after IVT in 5 eyes (83%) and deteriorated (3 fewer lines on Snellen 
charts) in 1 eye (17%). After PDT, BCVA remained stable in 2 eyes (33%) and deteriorated 
in 4 eyes (67%) (Table I). Overall, IVT treatment combined with PDT reduced fluores-
cein leakage (Figures 1– 4). Based on GLD, median lesion size increased 24% before PDT 
and 61% in 4 eyes 6 months after PDT (Table II). OCT showed a resolution or reduction 
of intraretinal and subretinal fluid accumulation (Figures 5–7).14 One eye had intraocular 
hypertension at 3 months and was treated with a combination of topical antiglaucomatous 
drops (β-blocker and carbonic anhydrase inhibitor). One eye developed a pigment epithe-
lial tear after PDT (Figures 4–7). There was 1 case of sterile endophthalmitis, which 
was treated with topical dexamethasone, tetracycline, and atropine.
DISCUSSION
In this study, we used the combination of IVT and PDT to treat R-RAP,33 because 
combining therapies offers the possibility of reducing the number of repeated treat-
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Table I.  Demographic and clinical characteristics in a retrospective case series of 5 patients (6 eyes) diagnosed with stage II 
recurrent retinal angiomatous proliferation who received photodynamic therapy (PDT) before and 1 month after intra- 
vitreal triamcinolone acetonide (IVT).
     Baseline     Post-IVT  Time 
  Age, Follow-up, Baseline IOP, Previous Pre-IVT Time to Post-IVT IOP, Post-IVT to PDT, BCVA at BCVA at BCVA at 
Pt Sex y d BCVA mm Hg PDT BCVA IVT, d BCVA mm Hg AE d 1 mo 3 mo 6 mo
1 M 79 225 20/40 14 1 20/40 67 20/100 15 None 22 20/200 20/200 20/200
2 M 73 194 20/50 15 1 20/320 120 20/320 14 None 11 20/400 20/320 20/320
3 F 73 119 20/50 14 2 20/400 11 20/400 25 Ocular 27 20/400 20/400 20/400 
           hypertension 
4 M 74 232 20/50 13 1 20/63 145 20/63 15 RPE tear 10 20/100 20/100 20/200
5 M 81 123 20/20 15 1 20/100 43 20/100 14 None 20 20/400 20/400 20/400
5 M 81 488 20/40 16 5 20/200 408 20/200 16 None 20 20/2000 20/2000 20/2000
Pt = patient; BCVA = best corrected visual acuity; IOP = intraocular pressure; AE = adverse event; M = male; F = female; RPE = retinal pigment epithelium.
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Figure 2.  Fluorescein angiography image of lesion of patient 4 at 15 days before intravit-
real triamcinolone acetonide (IVT), showing extensive pigment epithelial detach-
ment, in a case series of 5 patients with stage II recurrent retinal angiomatous 
proliferation who received photodynamic therapy before and 1 month after IVT.
Figure 1.  Fluorescein angiography image of lesion of patient 4 at baseline, showing jux-
tafoveal retinal angiomatous proliferation (RAP) surrounded by pigment epithe-
lial detachment, in a case series of 5 patients with stage II recurrent RAP who 
received photodynamic therapy before and 1 month after intravitreal triamcino-
lone acetonide.
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Figure 4.  Fluorescein angiography image of lesion of patient 4 at 6 months after photo-
dynamic therapy, showing a reduction in pigment epithelial detachment and of 
the pigment epithelial tear, in a case series of 5 patients with stage II recurrent 
retinal angiomatous proliferation who received photodynamic therapy before 
and 1 month after intravitreal triamcinolone acetonide.
Figure 3.  Fluorescein angiography image of lesion of patient 4 at 3 months after photo-
dynamic therapy, showing persistent pigment epithelial detachment and pig-
ment epithelial tear, in a case series of 5 patients with stage II recurrent retinal 
angiomatous proliferation who received photodynamic therapy before and 1 month 
after intravitreal triamcinolone acetonide.
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Table II.  Lesion size in microns, calculated using greatest linear dimension, in a retro-
spective case series of 5 patients (6 eyes) diagnosed with stage II recurrent 
retinal angiomatous proliferation who received photodynamic therapy (PDT) 
before and 1 month after intravitreal triamcinolone acetonide (IVT). Increase in 
lesion size indicates worsening disease. 
   6 Months 
Patient Baseline IVT Post-PDT Difference, %
1 2550 4997 5142 202
2 3670 5288 6075 166
3 2625 2175 2186 83
4 2775 6073 6089 219
5 3832 3696 6022 157
5 4095 4555 6085 149
Figure 5.  Optical coherence tomography image of patient 4 at baseline, showing pigment 
epithelial detachment contiguous to retinal angiomatous proliferation, in a case 
series of 5 patients with stage II recurrent retinal angiomatous proliferation 
who received photodynamic therapy before and 1 month after intravitreal triam-
cinolone acetonide.
Figure 6.  Optical coherence tomography image of patient 4 at 15 days before intravitreal 
triamcinolone acetonide (IVT), showing extensive pigment epithelial detach-
ment, in a case series of 5 patients with stage II recurrent retinal angiomatous 
proliferation who received photodynamic therapy before and 1 month after IVT.
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ments, thereby improving visual acuity.24,34 Despite the resolution of fluorescein and indo-
cyanine leakage, visual acuity decreased by 2 lines36,37 and lesion size increased 61% in 4 eyes 
(66%). The reduction of fluorescein and indocyanine leakage could be related to the antian-
giogenic effect and anti-inflammatory properties of corticosteroids. In particular, corticoster- 
oids can modulate the production of cytokines and reduce the permeability induced by 
vascular endothelial growth factor.37–39 These secondary effects would not be expected with 
PDT with verteporfin alone. The sequence and temporal interval of the combined treatments 
are likely to be important. In our study, PDT was performed within 1 month after IVT injec-
tion. During this period, triamcinolone could reduce fluorescein leakage and facilitate RPE 
reattachment, diminishing the risk of an RPE tear and sudden decrease in vision.40–43
Adverse events arising from the combined treatment may be expected to include 
all of those associated with PDT, as well as the incremental risks of IVT injection (eg, 
increased intraocular pressure, accelerated progression of cataract formation, endophthal- 
mitis).43 To balance intraocular pressure, we prescribed hypotensive topical therapy 
(β-blocker) after IVT injection for the entire follow-up period. Only 3 eyes needed to 
be treated with combination topical therapy (β-blocker and dorzolamide). Cataract 
progression was not observed because of the short duration of follow-up. There was 
1 case of sterile endophthalmitis, which was treated with topical dexamethasone, tetra- 
cycline, and atropine. A pigment epithelial tear occurred in 1 eye after PDT.
Limitations and potential biases of the present study were the retrospective nature 
of the investigation, the limited number of eyes, and the short follow-up period. 
Moreover, the small sample size and the relatively short follow-up period did not al-
low calculation of the power to detect complications throughout the follow-up period. 
Krebs et al44 did not find a beneficial effect of triamcinolone combined therapy versus 
PDT alone, suggesting new therapeutic strategies might be required in RAP lesions, 
probably including therapy with antiangiogenic agents.45
CONCLUSIONS
The findings of the present case series suggested that combination treatment with 
IVT injection followed 1 month later by PDT with verteporfin was not an effective or 
well-tolerated strategy to treat the eyes of these patients affected by R-RAP.
Figure 7.  Optical coherence tomography image of patient 4 at 6 months after photody-
namic therapy, showing fibrovascular tissue of the retinal pigment epithelium 
tear, in a case series of 5 patients with stage II recurrent retinal angiomatous 
proliferation who received photodynamic therapy before and 1 month after intra-
vitreal triamcinolone acetonide. 
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